Haematological Tumours

Coordinator: Ramón García / Co-coordinator: Dolors Colomer

Hematologic tumors, or malignant hemopathies, originate from cells in the blood tissue and represent 15% of all cancers. They have a significant socioeconomic impact as they are the most common in children and young adults.

This coordinated research program brings together the efforts of 8 specialized research groups dedicated to studying the major types of hematologic neoplasms. It involves researchers with extensive experience in integrated networked research. The program's objectives are focused on understanding the biology of these tumors, comprehending the mechanisms of progression and resistance, and identifying biomarkers to monitor the effectiveness of treatments. The ultimate goal is to contribute to better care and treatment for patients with hematologic tumors and to establish new treatment standards that can be applied in the daily clinical practice of our patients.

For these groups, CIBERONC represents the initiative that leads oncological research in a network, providing a significant opportunity to enhance the coordination of their activities related to malignant hemopathies and to focus on aspects that can benefit from the collaborative research of different groups, not only those within the hematology program but also from other programs.

Program objective:

• Clinical stratification of patients with malignant hemopathies based on the (epi)genomic and immunophenotypic characteristics of neoplastic cells and the tumor microenvironment.

Groups: